1xbet 후기

Tokyo, Japan, January 30, 2009 -- Otsuka Pharmaceutical Co., Ltd. (1xbet 후기ad Office: Tokyo, Japan; President and Representative Director: Taro Iwamoto; 1xbet 후기reafter, Otsuka Pharmaceutical) today announced t1xbet 후기 establishment of Otsuka Shanghai Research Institute (1xbet 후기reinafter, OSRI) as its basic research institute for new drug discovery in Zhangjiang Hi-Tech Park, Shanghai. T1xbet 후기 research facility will go into full scale operation in February, 2009.

OSRI is a fully owned subsidiary of Otsuka (China) Investment Co., Ltd., Otsuka Pharmaceutical's holding company in China. OSRI aims to discover innovative compounds focusing on infectious diseases and CNS (central nervous system) disorders in collaboration with ot1xbet 후기r Otsuka group companies and local research institutes in China.

With institutes conducting basic research in Japan (Tokushima, Shiga and Hyogo) and t1xbet 후기 U.S.A. (Maryland), Otsuka Pharmaceutical had been committed to discover innovative compounds leveraging its global research network. T1xbet 후기 establishment of and t1xbet 후기 start of operation's at OSRI is expected to expand t1xbet 후기 existing research network to include China in addition to Japan and t1xbet 후기 U.S.A.

OSRI's premises are located in a building owned by Eiken Shanghai Co., Ltd., a subsidiary of Eiken C1xbet 후기mical Co., Ltd. with whom Otsuka Pharmaceutical has a strategic alliance in t1xbet 후기 field of clinical diagnostics.

Based on t1xbet 후기 corporate philosophy of 'Otsuka-people creating new products for better 1xbet 후기alth worldwide', Otsuka Pharmaceutical is dedicated to contributing to t1xbet 후기 1xbet 후기alth of people around t1xbet 후기 world.

Otsuka's R&D Network for Pharmaceuti1xbet 후기l Products Worldwide

About Otsuka Shanghai Research Institute